Ratings by Morgan Stanley (Michael E. Ulz)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/21/2026 | Arrowhead Pharma | ARWR | Upgrade | Overweight (Equalweight) |
69.51 (81.78) |
17.65% | Details | |
| 2/6/2026 | Arrowhead Pharma | ARWR | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/27/2026 | Arrowhead Pharma | ARWR | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/7/2026 | Arrowhead Pharma | ARWR | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/26/2025 | Arrowhead Pharma | ARWR | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/11/2025 | Arrowhead Pharma | ARWR | Maintain | Equalweight (N/A) |
|
Details |
